Found 307 Results
Page 4 of 31
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]
04/21/2021
This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]
04/12/2021
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]
Tags: AsiDNA™, OX401
04/08/2021
Watch the interview (in French)
03/26/2021
The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]
Tags: Financials & Corporate
03/24/2021
This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]
03/10/2021
This study is supported by a grant from the European Fight Kids Cancer program[1] Paris (France), February 4, 2021 […]
02/04/2021
Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]
02/02/2021
This financing extends the Company’s cash horizon to the 3rd quarter of 2022 Paris (France), January 28, 2021 – […]
01/28/2021
Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
01/11/2021
Page 4 of 31
